Observational study on the potential mechanism of SiNi powder in the treatment of ulcerative colitis based on network pharmacology and machine learning
Abstract
Background/ Aim. Chronic idiopathic ulcerative colitis (UC) damages and disrupts the intestinal mucosa. Diagnosing UC and differential diagnosis is tough. Its anti-inflammatory and immunosuppressive properties make SiNi powder (SNP) a popular treatment for inflammatory illnesses. The multi-target mechanism of SNP on UC is unknown. The aim of this study was to examine the potential mechanisms of SNP in UC treatment through network pharmacology and machine learning approaches, identify novel diagnostic biomarkers, and develop a predictive model for UC diagnosis. Methods. The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) assessed active constituents and target proteins. Using two public datasets (GSE87473 and GSE75214), differential analysis was conducted on the gene expression matrix of UC to find the intersection of differentially expressed genes and SNP-related targets. Hub genes were assessed using several machine-learning algorithms to create a prediction model. Single-cell analysis studies were used to diagnose genes and immune cells. NetworkAnalyst predicted upstream transcription factors, micro-ribonucleic acids, and the protein-compound network. Results. According to the TCMSP database, the SNP included 95 active constituents and 795 associated targets against UC. After identifying 79 overlapping genes, machine learning discovered five hub genes: TRPV1, ABCG2, BACE2, MMP3, and LIPC. Diagnostics were verified using external datasets. These genes were used to create a predictive model with a large area under the curve (AUC = 1,000) and an external validation dataset with 1,000 AUCs, demonstrating excellent accuracy of the predictive model and the hub genes. Conclusion. SNP and UC are associated, and hub genes were found to evaluate UC risk. This computational technique opens new avenues for UC biomarker and therapeutic target research, although further experimental validation is required to confirm and validate these results.
References
Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and path-ophysiology of inflammatory bowel disease. Clin Microbiol Rev 2002; 15(1): 79–94.
Levine JS, Burakoff R. Extraintestinal manifestations of in-flammatory bowel disease. Gastroenterol Hepatol (N Y) 2011; 7(4): 235–41.
Gordon H, Burisch J, Ellul P, Karmiris K, Katsanos K, Allocca M, et al. ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis 2024; 18(1): 1–37.
Fanizzi F, Allocca M, Fiorino G, Zilli A, Furfaro F, Parigi TL, et al. Raising the bar in ulcerative colitis management. Therap Adv Gastroenterol 2024; 17: 17562848241273066.
Zeng Y, Zhang JW, Yang J. Optimal traditional Chinese medi-cine formulas in treating ulcerative colitis: Choose one or take it all? World J Clin Cases 2024; 12(32): 6570–4.
Wang M, Fu R, Xu D, Chen Y, Yue S, Zhang S, et al. Tradition-al Chinese Medicine: A promising strategy to regulate the im-balance of bacterial flora, impaired intestinal barrier and im-mune function attributed to ulcerative colitis through intesti-nal microecology. J Ethnopharmacol 2024; 318(Pt A): 116879.
Qi Q, Liu YN, Jin XM, Zhang LS, Wang C, Bao CH, et al. Moxibustion treatment modulates the gut microbiota and immune function in a dextran sulphate sodium-induced colitis rat model. World J Gastroenterol 2018; 24(28): 3130–44.
Li L, Yang L, Yang L, He C, He Y, Chen L, et al. Network pharmacology: a bright guiding light on the way to explore the personalized precise medication of traditional Chinese medi-cine. Chin Med 2023; 18(1): 146.
Feng W, Zhu L, Shen H. Traditional Chinese Medicine Allevi-ates Ulcerative Colitis via Modulating Gut Microbiota. Evid Based Complement Alternat Med 2022; 2022: 8075344.
Liang Y, Li Y, Lee C, Yu Z, Chen C, Liang C. Ulcerative coli-tis: molecular insights and intervention therapy. Mol Biomed 2024; 5(1): 42.
Noor F, Tahir ul Qamar M, Ashfaq UA, Albutti A, Alwashmi ASS, Aljasir MA. Network Pharmacology Approach for Me-dicinal Plants: Review and Assessment. Pharmaceuticals 2022; 15(5): 572.
Fishilevich S, Nudel R, Rappaport N, Hadar R, Plaschkes I, Iny Stein T, et al. GeneHancer: genome-wide integration of en-hancers and target genes in GeneCards. Database (Oxford) 2017; 2017: bax028.
Nasr S, Dahmani W, Jaziri H, Hammami A, Slama AB, Ameur WB, et al. Exploring work productivity loss in patients with inflammatory bowel disease. Future Sci OA 2023; 9(8): FSO872.
Liu S, Eisenstein S. State-of-the-art surgery for ulcerative coli-tis. Langenbecks Arch Surg 2021; 406(6): 1751–61.
Li S, Huang M, Wu G, Huang W, Huang Z, Yang X, et al. Effi-cacy of Chinese Herbal Formula Sini Zuojin Decoction in Treating Gastroesophageal Reflux Disease: Clinical Evidence and Potential Mechanisms. Front Pharmacol 2020; 11: 76.
Saez A, Herrero-Fernandez B, Gomez-Bris R, Sánchez-Martinez H, Gonzalez-Granado JM. Pathophysiology of Inflammatory Bowel Disease: Innate Immune System. Int J Mol Sci 2023; 24(2): 1526.
Csekő K, Beckers B, Keszthelyi D, Helyes Z. Role of TRPV1 and TRPA1 Ion Channels in Inflammatory Bowel Diseases: Poten-tial Therapeutic Targets? Pharmaceuticals (Basel) 2019; 12(2): 48.
Quaglio AEV, Santaella FJ, Rodrigues MAM, Sassaki LY, Di Stasi LC. MicroRNAs expression influence in ulcerative colitis and Crohn's disease: A pilot study for the identification of di-agnostic biomarkers. World J Gastroenterol 2021; 27(45): 7801–12.
Wu F, Zikusoka M, Trindade A, Dassopoulos T, Harris ML, Bay-less TM, et al. MicroRNAs are differentially expressed in ul-cerative colitis and alter expression of macrophage inflamma-tory peptide-2 alpha. Gastroenterology 2008; 135(5): 1624–35.e24.
Vassar R, Kuhn PH, Haass C, Kennedy ME, Rajendran L, Wong PC, et al. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J Neu-rochem 2014; 130(1): 4–28.
Kofla-Dłubacz A, Matusiewicz M, Krzesiek E, Noga L, Iwańczak B. Metalloproteinase-3 and -9 as novel markers in the evalua-tion of ulcerative colitis activity in children. Adv Clin Exp Med 2014; 23(1): 103–10.
Tian M, Qi Y, Zhang X, Wu Z, Chen J, Chen F, et al. Regulation of the JAK2-STAT5 Pathway by Signaling Molecules in the Mammary Gland. Front Cell Dev Biol 2020; 8: 604896.
Mora-Buch R, Dotti I, Planell N, Calderón-Gómez E, Jung P, Masamunt MC, et al. Epithelial IL-1R2 acts as a homeostatic regulator during remission of ulcerative colitis. Mucosal Im-munol 2016; 9(4): 950–9.
Adolph TE, Meyer M, Jukic A, Tilg H. Heavy arch: from in-flammatory bowel diseases to metabolic disorders. Gut 2024; 73(8): 1376–87.
Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obe-sity and metabolic disease. J Clin Invest 2017; 127(1): 1–4.
Zhang S, Zhang G, Wang W, Guo SB, Zhang P, Wang F, et al. An assessment system for clinical and biological interpretability in ulcerative colitis. Aging (Albany NY) 2024; 16(4): 3856–79.
Vălean D, Zaharie R, Țaulean R, Usatiuc L, Zaharie F. Recent Trends in Non-Invasive Methods of Diagnosis and Evaluation of Inflammatory Bowel Disease: A Short Review. Int J Mol Sci 2024; 25(4): 2077.
Kulkarni C, Liu D, Fardeen T, Dickson ER, Jang H, Sinha SR, et al. Artificial intelligence and machine learning technologies in ulcerative colitis. Therap Adv Gastroenterol 2024; 17: 17562848241272001.
Yousef M, Allmer J. Deep learning in bioinformatics. Turk J Biol 2023; 47(6): 366–82.